BEQVEZ (fidanacogene elaparvovec)

TherapyPfizer

BEQVEZ (fidanacogene elaparvovec) from Pfizer is a gene therapy designed for eligible adults with hemophilia B.

Approvals

Indications

Biomarkers

Mapped tests

Where this therapy is approved with a companion diagnostic

Each row represents a defined combination of indication, biomarker criteria, and BEQVEZ. Select a testing pathway to see the eligible companion diagnostic tests.

Indication-specific approvals

Approvals where BEQVEZ is tied to a specific indication and biomarker definition.

Indication	Biomarker criteria	Notes
Moderate to severe Hemophilia B patients Non-cancer · Blood	AAV Antibodies serotype rh74		View testing pathway →

Tumor-agnostic approvals

Approvals defined at the solid tumor level where biomarker criteria determine eligibility for BEQVEZ.

No tumor-agnostic companion diagnostic approvals are currently mapped for this therapy.

Tests used in these approvals

These assays are identified in FDA labeling or sponsor materials as companion diagnostics or acceptable tests when considering BEQVEZ for eligible patients.

Test

nAbCyte Anti-AAVRh74var HB-FE Assay

Labcorp

Method

AAV_Antibody

Specimen

Serum

1 approvalView test profile →

This view is scoped to BEQVEZ (fidanacogene elaparvovec). You can also see how it compares with other therapies and indications on the main Know Your Companions™ map.